Kennedy Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Kennedy Capital Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-53,742	Closed	-$946K	–	761
2016 Q2	$946K	Sell	53,742 -554	-1%	-$8.97K	0.02%	652
2016 Q1	$660K	Buy	54,296 +6,787	+14%	+$107K	0.01%	683
2015 Q4	$1.16M	Buy	47,509 +478	+1%	+$11.2K	0.02%	646
2015 Q3	$834K	Sell	47,031 -15,091	-24%	-$273K	0.02%	665
2015 Q2	$1.1M	Sell	62,122 -257	-0.4%	-$4.71K	0.02%	663
2015 Q1	$1.96M	Buy	62,379 +9,198	+17%	+$267K	0.03%	580
2014 Q4	$1.55M	Buy	53,181 +36,066	+211%	+$915K	0.03%	606
2014 Q3	$354K	Buy	+17,115	New	+$337K	0.01%	741

Other funds holding AERI

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Kennedy Capital Management's AERI Position: Q3 2016 in Review

Kennedy Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q3 2016, closing a stake of 53,742 shares — an estimated $946K sold.

Kennedy Capital Management first reported a position in AERI in Q3 2014 and held it in 8 quarters. The position peaked at $1.96M in Q1 2015. 162 funds tracked by Wall St. Rank hold AERI as of Q3 2016.

Kennedy Capital Management reported no remaining Aerie Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Kennedy Capital Management sold 53,742 Aerie Pharmaceuticals shares in Q3 2016, an estimated $946K.
Kennedy Capital Management first reported a position in Aerie Pharmaceuticals in Q3 2014 and held it in 8 quarters.
Kennedy Capital Management's Aerie Pharmaceuticals position peaked at $1.96M in Q1 2015.
162 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2016.

Based on Kennedy Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.